Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nisotirostide + Tirzepatide in Overweight or Obese Participants
NCT05582096Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing LY3457263 + Tirzepatide with Placebo + Tirzepatide (2 arms). Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) at 11 weeks. Started Nov 2022; status: completed.
02
Drugs
nisotirostide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05582096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582096.